These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 19086328)

  • 1. Review article: panitumumab--a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer.
    Peeters M; Balfour J; Arnold D
    Aliment Pharmacol Ther; 2008 Aug; 28(3):269-81. PubMed ID: 19086328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
    Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
    Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.
    Wadlow RC; Hezel AF; Abrams TA; Blaszkowsky LS; Fuchs CS; Kulke MH; Kwak EL; Meyerhardt JA; Ryan DP; Szymonifka J; Wolpin BM; Zhu AX; Clark JW
    Oncologist; 2012; 17(1):14. PubMed ID: 22210091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.
    Reidy DL; Vakiani E; Fakih MG; Saif MW; Hecht JR; Goodman-Davis N; Hollywood E; Shia J; Schwartz J; Chandrawansa K; Dontabhaktuni A; Youssoufian H; Solit DB; Saltz LB
    J Clin Oncol; 2010 Sep; 28(27):4240-6. PubMed ID: 20713879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration of panitumumab into the treatment of colorectal cancer.
    Gravalos C; Cassinello J; García-Alfonso P; Jimeno A
    Crit Rev Oncol Hematol; 2010 Apr; 74(1):16-26. PubMed ID: 19616446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
    Amado RG; Wolf M; Peeters M; Van Cutsem E; Siena S; Freeman DJ; Juan T; Sikorski R; Suggs S; Radinsky R; Patterson SD; Chang DD
    J Clin Oncol; 2008 Apr; 26(10):1626-34. PubMed ID: 18316791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
    Peeters M; Douillard JY; Van Cutsem E; Siena S; Zhang K; Williams R; Wiezorek J
    J Clin Oncol; 2013 Feb; 31(6):759-65. PubMed ID: 23182985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.
    Price TJ; Peeters M; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Zhang K; Murugappan S; Sidhu R
    Lancet Oncol; 2014 May; 15(6):569-79. PubMed ID: 24739896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial).
    Akiyoshi K; Hamaguchi T; Yoshimura K; Takahashi N; Honma Y; Iwasa S; Takashima A; Kato K; Yamada Y; Onodera H; Takeshita S; Yasui H; Sakai G; Akatsuka S; Ogawa K; Horita Y; Nagai Y; Shimada Y
    Clin Colorectal Cancer; 2018 Mar; 17(1):e83-e89. PubMed ID: 29169974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients.
    Kiss I; Mlcochova J; Bortlicek Z; Poprach A; Drabek J; Vychytilova-Faltejskova P; Svoboda M; Buchler T; Batko S; Ryska A; Hajduch M; Slaby O
    Anticancer Res; 2016 Sep; 36(9):4955-9. PubMed ID: 27630355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Panitumumab: a review of its use in metastatic colorectal cancer.
    Keating GM
    Drugs; 2010 May; 70(8):1059-78. PubMed ID: 20481659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies in older adults with metastatic colorectal cancer.
    Dotan E; Devarajan K; D'Silva AJ; Beck A; Kloth DD; Cohen SJ; Denlinger C
    Clin Colorectal Cancer; 2014 Sep; 13(3):192-8. PubMed ID: 25074246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
    Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
    Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond.
    Ballestrero A; Garuti A; Cirmena G; Rocco I; Palermo C; Nencioni A; Scabini S; Zoppoli G; Parodi S; Patrone F
    Curr Cancer Drug Targets; 2012 May; 12(4):316-28. PubMed ID: 22385512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.
    Martin V; Landi L; Molinari F; Fountzilas G; Geva R; Riva A; Saletti P; De Dosso S; Spitale A; Tejpar S; Kalogeras KT; Mazzucchelli L; Frattini M; Cappuzzo F
    Br J Cancer; 2013 Feb; 108(3):668-75. PubMed ID: 23348520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
    Cohn AL; Shumaker GC; Khandelwal P; Smith DA; Neubauer MA; Mehta N; Richards D; Watkins DL; Zhang K; Yassine MR
    Clin Colorectal Cancer; 2011 Sep; 10(3):171-7. PubMed ID: 21855038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.
    Dahabreh IJ; Terasawa T; Castaldi PJ; Trikalinos TA
    Ann Intern Med; 2011 Jan; 154(1):37-49. PubMed ID: 21200037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.